It has been estimated that 49% of patients treated with anti–PD-1 will develop skin toxicity. 2 The breadth of cutaneous adverse reactions to anti–PD-1 treatment have yet to be fully …

The use of antibodies to programmed cell death-1 receptor and its ligand (PD-1/PD-L1) has revolutionized treatment in patients with advanced skin cancer and produced long-term, …

The efficacy of anti-PD-1/PD-ligand (L)1 antibodies in melanoma and other solid tumors is well established. Two anti-PD-1 antibodies have also been approved for the treatment of advanced …

Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on …

PD-1 is an inhibitor receptor that is expressed to a large extent in T lymphocytes and responsible for regulating autoimmunity and self-tolerance. In this study, we aimed to investigate the …

In this review, we describe common molecular features of skin cancers that may render them particularly susceptible to anti-PD-1/PD-L1 and detail results from key clinical trials of these …

Nov 21, 2022 · Clinically, immune-related cutaneous toxic effects mainly include skin rashes, pruritus, and vitiligo. In severe cases, such as Stevens-Johnson syndrome (SJS) or toxic …

May 17, 2019 · Compared with patients receiving chemotherapy, PD-1/PD-L1 inhibitor treated patients had higher risk of developing rash (RR = 1.84), pruritus (RR = 3.74) and vitiligo (RR = …

Jun 4, 2018 · Cemiplimab is a high-affinity, highly potent human monoclonal antibody directed against programmed death 1 (PD-1). 15 In the dose-escalation portion of the phase 1 study of …

PD-1 inhibition produces durable responses among patients with advanced or metastatic CSCC. PD-1 inhibition therapy is well tolerated, but patients should be monitored closely for immune …